NRx Pharmaceuticals forms defense subsidiary for military therapy research
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
April 15, 2026 7:00 AM EDTDr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve as first President of NRx Defense SystemsDevelopment initiative to be conducted through NRx Defense Systems, Inc., a newly incorporated R&D subsidiary, in partnership with Zeta Surgical, Inc. Initial focus will be the development of Combined Neuroplastic Therapy including D-Cycloserine (NRX-101) and Robotic-enabled Transcranial Magnetic Stimulation in the military and first-responder setting
MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- NRx... More
